Case report: ALK D1225N missense mutation in lung adenocarcinoma responds to tyrosine kinase inhibitors
ALK gene missense mutations are conventionally considered non-driver mutations without pathological significance, and therefore, there is a lack of effective target drugs against them. The standard treatment option for patients with ALK missense mutations is chemotherapy with or without antiangiogen...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Book |
| Published: |
Frontiers Media S.A.,
2023-07-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|